(Q36909385)

17 August 2017

1 reference

title

Biologics in Crohn's disease: searching indicators for outcome (English)

1 reference

17 August 2017

0 references

C Janneke van der Woude

series ordinal

1

1 reference

17 August 2017

Daniel W Hommes

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

1233-1243

1 reference

Role of cytokines in the pathogenesis of inflammatory bowel disease

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Mucosal immunity in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Innate immunity and apoptosis in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Activation of nuclear factor kappa B inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Biologic therapy of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Review article: the burden of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

The complicated path to true causes of disease: role of nuclear factor kappaB in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1233

10.1517/14712598.7.8.1233

21 January 2018

Identifiers

DOI

1 reference

release_qe4jibpcfzavto4scg6wkutnqy

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qe4jibpcfzavto4scg6wkutnqy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference